← All trials
NCT05880394
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Jul 31, 2024
- First posted
- May 30, 2023
- Last posted
- Sep 28, 2023
- Enrollment
- 30
- Arms / groups
- — / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hoag Memorial Hospital PresbyterianLead sponsor
- Hoag Memorial Hospital PresbyterianOverall official - principal investigator
- Hoag Memorial Hospital PresbyterianReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.